<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00259727</url>
  </required_header>
  <id_info>
    <org_study_id>RCD-005-05S</org_study_id>
    <nct_id>NCT00259727</nct_id>
  </id_info>
  <brief_title>The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism</brief_title>
  <official_title>The Effects of HIV Protease Inhibitors on Glucose Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the mechanisms by which HIV protease inhibitors&#xD;
      contribute to the development of diabetes in HIV-infected patients. The investigators propose&#xD;
      that some HIV protease inhibitors impair insulin secretion and increase the production of&#xD;
      glucose by the liver.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV protease inhibitors (PIs) have been associated with type 2 diabetes. To design future HIV&#xD;
      drugs that have have the least adverse metabolic effects, it is necessary to identify the&#xD;
      disorders of glucose metabolism with PI therapy. Previously PIs have been shown to acutely&#xD;
      induce insulin resistance in the periphery. Preliminary data show that PIs also impair&#xD;
      insulin secretion and increase hepatic glucose production in humans. These lesions are key&#xD;
      contributors to the development of type 2 diabetes. Due to the difficulty in separating out&#xD;
      factors related to HIV infection from the direct effect of PIs, an effective design is to&#xD;
      study HIV-negative subjects to define the direct effects of PIs on the liver and pancreas on&#xD;
      glucose metabolism:&#xD;
&#xD;
      Specific Aim 1: To determine which PIs acutely inhibit insulin secretion in humans;&#xD;
      randomized, double-blind, placebo-controlled trials will be performed on healthy normal&#xD;
      volunteers given either a single dose of PI or placebo using the hyperglycemic clamp to&#xD;
      assess insulin secretion in relation to insulin sensitivity.&#xD;
&#xD;
      Specific Aim 2: To determine which PIs acutely increase hepatic glucose production,&#xD;
      glycogenolysis, and gluconeogenesis; measurements will be assessed in the fasting and&#xD;
      hyperinsulinemic states using stable isotope analysis techniques. Samples have already been&#xD;
      collected from double-blind, placebo-controlled trials of the effects of a single dose of PI&#xD;
      on insulin sensitivity during the euglycemic hyperinsulinemic clamp.&#xD;
&#xD;
      Specific Aim 3: To determine the mechanism by which certain PIs increase hepatic glucose&#xD;
      production; an infusion of somatostatin during the fasting state and hyperinsulinemic state&#xD;
      will be used to suppress the effects of glucagon. Subjects will undergo a randomized,&#xD;
      double-blind, placebo-controlled trial of a single dose of PI or placebo on insulin&#xD;
      sensitivity using the euglycemic hyperinsulinemic clamp. Somatostatin, glucagon, and growth&#xD;
      hormone will be infused before and during the clamp study. Hepatic glucose production,&#xD;
      glycogenolysis, and gluconeogenesis will be assessed using stable isotope tracer techniques.&#xD;
      Results will be compared to PIs acutely given in the absence of somatostatin, as stated in&#xD;
      Specific Aim 2.&#xD;
&#xD;
      Determination of the effects of PI therapy allows clinicians to identify patients who may be&#xD;
      at particular risk for developing diabetes on certain PIs and treat them more effectively. In&#xD;
      the future, drugs for the treatment of HIV can be developed that avoid these disorders of&#xD;
      glucose metabolism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Insulin secretion after a single dose of HIV protease inhibitor versus placebo (insulin secretion assessed by using the hyperglycemic clamp technique)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatic glucose production, glycogenolysis, and gluconeogenesis after a single dose of HIV protease inhibitor versus placebo (stable isotope analysis with mass isotopic distribution analysis)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic glucose production during a somatostatin infusion in the fasting and hyperinsulinemic state after a single dose of HIV protease inhibitor</measure>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetes</condition>
  <condition>HIV Infections</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
  </arm_group>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, HIV-negative volunteers between the ages of 18-72 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any subject with states known to be associated with insulin resistance, such as&#xD;
             impaired fasting glucose (glucose &gt; 110 mg/dl), overweight (body mass index [BMI] &gt;&#xD;
             27), dyslipidemia (triglycerides &gt; 150 mg/dl), hypertension (blood pressure [BP] &gt;&#xD;
             130/85 mmHg or on medication), renal disease, systemic use of glucocorticoids, growth&#xD;
             hormone, niacin, or antipsychotics.&#xD;
&#xD;
          -  Women will be tested for pregnancy immediately prior to study and excluded if&#xD;
             pregnant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, Grunfeld C. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS. 2001 May 4;15(7):F11-8.</citation>
    <PMID>11399973</PMID>
  </results_reference>
  <results_reference>
    <citation>Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS. 2002 Mar 29;16(5):F1-8.</citation>
    <PMID>11964551</PMID>
  </results_reference>
  <results_reference>
    <citation>Woerle HJ, Mariuz PR, Meyer C, Reichman RC, Popa EM, Dostou JM, Welle SL, Gerich JE. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes. 2003 Apr;52(4):918-25.</citation>
    <PMID>12663461</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, Mulligan K, Schambelan M, Grunfeld C. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS. 2004 Mar 5;18(4):641-9.</citation>
    <PMID>15090769</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee GA, Mafong DD, Noor MA, Lo JC, Mulligan K, Schwarz JM, Schambelan M, Grunfeld C. HIV protease inhibitors increase adiponectin levels in HIV-negative men. J Acquir Immune Defic Syndr. 2004 May 1;36(1):645-7.</citation>
    <PMID>15097312</PMID>
  </results_reference>
  <results_reference>
    <citation>Schwarz JM, Lee GA, Park S, Noor MA, Lee J, Wen M, Lo JC, Mulligan K, Schambelan M, Grunfeld C. Indinavir increases glucose production in healthy HIV-negative men. AIDS. 2004 Sep 3;18(13):1852-4.</citation>
    <PMID>15316349</PMID>
  </results_reference>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>November 28, 2005</study_first_submitted>
  <study_first_submitted_qc>November 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2005</study_first_posted>
  <last_update_submitted>September 28, 2009</last_update_submitted>
  <last_update_submitted_qc>September 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Lee, Grace - Principal Investigator</name_title>
    <organization>Department of Veterans Affairs</organization>
  </responsible_party>
  <keyword>Amprenavir</keyword>
  <keyword>Glucagon</keyword>
  <keyword>HIV Protease inhibitors</keyword>
  <keyword>Indinavir</keyword>
  <keyword>Lopinavir</keyword>
  <keyword>Ritonavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

